Trial Profile
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Spartalizumab (Primary) ; Taminadenant (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colon cancer; Colorectal cancer; Diffuse large B cell lymphoma; Head and neck cancer; Male breast cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 14 Jun 2023 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 11 Apr 2023 Status changed from active, no longer recruiting to discontinued.
- 30 Mar 2023 This trial has been discontinued in Spain, according to European Clinical Trials Database record.